Skip to main content

Farrell Michael J.'s Form 4 filing

Resmed Inc (RMD) · filed Mar 16, 2022

Accession no.
0001127602-22-009461
Filed
Mar 16, 2022
Trade date
Mar 15, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.38M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Farrell Michael J.CIK 0001485164Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 15, 2022ResMed Common StockMOption exerciseAcquired+5,675$57.76+$327,788410,904Direct
Mar 15, 2022ResMed Common StockSSaleDisposed−5,675$242.37F2−$1,375,449.75405,229Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 15, 2022ResMed Common StockMOption exerciseDisposed−5,675$0.00$0116,965Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $238.87 to $244.98. The price reported above reflects the weighted average sale price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)